Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judy R van Beijnum

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Angiogenesis|May 6, 2017
miRNAs: micro-managers of anticancer combination therapiesJudy R van Beijnum, Elisa Giovannetti, Dennis Poel, et al.
Angiogenesis|July 21, 2017
Erratum to: miRNAs: micro-managers of anticancer combination therapiesJudy R van Beijnum, Elisa Giovannetti, Dennis Poel, et al.
Current Pharmaceutical Design|January 29, 2008
Identification of novel drug targets for angiostatic cancer therapy; it takes two to tangoVictor L J L Thijssen, Judy R van Beijnum, Kevin H Mayo, et al.
Angiogenesis|October 20, 2019
The tumor vasculature an attractive CAR T cell target in solid tumorsParvin Akbari, Elisabeth J M Huijbers, Maria Themeli, et al.
Nature Protocols|June 13, 2008
Isolation of endothelial cells from fresh tissuesJudy R van Beijnum, Mat Rousch, Karolien Castermans, et al.
Angiogenesis|September 28, 2017
A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7)Judy R van Beijnum, Patrycja Nowak-Sliwinska, Maaike van Berkel, et al.
Angiogenesis|March 13, 2026
The vascular contribution to immunotherapy successArjan W Griffioen, Judy R van Beijnum, Sacha Jacobs, et al.
Pharmacological Reviews|March 15, 2015
The great escape; the hallmarks of resistance to antiangiogenic therapyJudy R van Beijnum, Patrycja Nowak-Sliwinska, Elisabeth J M Huijbers, et al.
Angiogenesis|September 16, 2010
Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membranePatrycja Nowak-Sliwinska, Judy R van Beijnum, Maaike van Berkel, et al.
Nature Reviews. Clinical Oncology|April 9, 2021
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomesZowi R Huinen, Elisabeth J M Huijbers, Judy R van Beijnum, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Angiogenesis|May 6, 2017
miRNAs: micro-managers of anticancer combination therapiesJudy R van Beijnum, Elisa Giovannetti, Dennis Poel, et al.
Angiogenesis|July 21, 2017
Erratum to: miRNAs: micro-managers of anticancer combination therapiesJudy R van Beijnum, Elisa Giovannetti, Dennis Poel, et al.
Current Pharmaceutical Design|January 29, 2008
Identification of novel drug targets for angiostatic cancer therapy; it takes two to tangoVictor L J L Thijssen, Judy R van Beijnum, Kevin H Mayo, et al.
Angiogenesis|October 20, 2019
The tumor vasculature an attractive CAR T cell target in solid tumorsParvin Akbari, Elisabeth J M Huijbers, Maria Themeli, et al.
Nature Protocols|June 13, 2008
Isolation of endothelial cells from fresh tissuesJudy R van Beijnum, Mat Rousch, Karolien Castermans, et al.
Angiogenesis|September 28, 2017
A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7)Judy R van Beijnum, Patrycja Nowak-Sliwinska, Maaike van Berkel, et al.
Angiogenesis|March 13, 2026
The vascular contribution to immunotherapy successArjan W Griffioen, Judy R van Beijnum, Sacha Jacobs, et al.
Pharmacological Reviews|March 15, 2015
The great escape; the hallmarks of resistance to antiangiogenic therapyJudy R van Beijnum, Patrycja Nowak-Sliwinska, Elisabeth J M Huijbers, et al.
Angiogenesis|September 16, 2010
Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membranePatrycja Nowak-Sliwinska, Judy R van Beijnum, Maaike van Berkel, et al.
Nature Reviews. Clinical Oncology|April 9, 2021
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomesZowi R Huinen, Elisabeth J M Huijbers, Judy R van Beijnum, et al.
Pageof 7